98 related articles for article (PubMed ID: 22136516)
1. Differential effect of oral dehydroepiandrosterone-sulphate on metabolic syndrome features in pre- and postmenopausal obese women.
Gómez-Santos C; Hernández-Morante JJ; Tébar FJ; Granero E; Garaulet M
Clin Endocrinol (Oxf); 2012 Oct; 77(4):548-54. PubMed ID: 22136516
[TBL] [Abstract][Full Text] [Related]
2. Dehydroepiandrosterone-sulphate replacement improves the human plasma fatty acid profile in plasma of obese women.
Gómez-Santos C; Larqué E; Granero E; Hernández-Morante JJ; Garaulet M
Steroids; 2011 Dec; 76(13):1425-32. PubMed ID: 21840329
[TBL] [Abstract][Full Text] [Related]
3. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women.
Diamond P; Cusan L; Gomez JL; Bélanger A; Labrie F
J Endocrinol; 1996 Sep; 150 Suppl():S43-50. PubMed ID: 8943786
[TBL] [Abstract][Full Text] [Related]
5. SHBG levels correlate with insulin resistance in postmenopausal women.
Akin F; Bastemir M; Alkiş E; Kaptanoglu B
Eur J Intern Med; 2009 Mar; 20(2):162-7. PubMed ID: 19327605
[TBL] [Abstract][Full Text] [Related]
6. Dehydroepiandrosterone sulfate levels in women. Relationships with body mass index, insulin and glucose levels.
Al-Harithy RN
Saudi Med J; 2003 Aug; 24(8):837-41. PubMed ID: 12939667
[TBL] [Abstract][Full Text] [Related]
7. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
8. Dhea supplementation and cognition in postmenopausal women.
Parsons TD; Kratz KM; Thompson E; Stanczyk FZ; Buckwalter JG
Int J Neurosci; 2006 Feb; 116(2):141-55. PubMed ID: 16393880
[TBL] [Abstract][Full Text] [Related]
9. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome.
Chu MC; Cosper P; Nakhuda GS; Lobo RA
Fertil Steril; 2006 Dec; 86(6):1669-75. PubMed ID: 17074346
[TBL] [Abstract][Full Text] [Related]
10. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjögren syndrome: a randomised controlled trial.
Hartkamp A; Geenen R; Godaert GL; Bootsma H; Kruize AA; Bijlsma JW; Derksen RH
Ann Rheum Dis; 2008 Jan; 67(1):91-7. PubMed ID: 17545193
[TBL] [Abstract][Full Text] [Related]
11. The effect of estrogen plus progestin treatment on sleep: a randomized, placebo-controlled, double-blind trial in premenopausal and late postmenopausal women.
Kalleinen N; Polo O; Himanen SL; Joutsen A; Polo-Kantola P
Climacteric; 2008 Jun; 11(3):233-43. PubMed ID: 18568788
[TBL] [Abstract][Full Text] [Related]
12. Endocrine effects of oral dehydroepiandrosterone in men with HIV infection: a prospective, randomized, double-blind, placebo-controlled trial.
Poretsky L; Brillon DJ; Ferrando S; Chiu J; McElhiney M; Ferenczi A; Sison MC; Haller I; Rabkin J
Metabolism; 2006 Jul; 55(7):858-70. PubMed ID: 16784956
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
Aquilante CL; Kosmiski LA; Zineh I; Rome LC; Knutsen SD
Pharmacotherapy; 2010 Mar; 30(3):236-47. PubMed ID: 20180607
[TBL] [Abstract][Full Text] [Related]
14. Effect of 6 months of exercise and isoflavone supplementation on clinical cardiovascular risk factors in obese postmenopausal women: a randomized, double-blind study.
Aubertin-Leheudre M; Lord C; Khalil A; Dionne IJ
Menopause; 2007; 14(4):624-9. PubMed ID: 17290158
[TBL] [Abstract][Full Text] [Related]
15. Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial.
Binder G; Weber S; Ehrismann M; Zaiser N; Meisner C; Ranke MB; Maier L; Wudy SA; Hartmann MF; Heinrich U; Bettendorf M; Doerr HG; Pfaeffle RW; Keller E;
J Clin Endocrinol Metab; 2009 Apr; 94(4):1182-90. PubMed ID: 19126625
[TBL] [Abstract][Full Text] [Related]
16. [Derivatives of dehydroepiandrosterone and their changes during a one-day starvation test].
Matoulek M; Hampl R; Svacina S; Sulcová J; Haas T
Cas Lek Cesk; 2000 Dec; 139(24):772-5. PubMed ID: 11262916
[TBL] [Abstract][Full Text] [Related]
17. Is there a threshold of visceral fat loss that improves the metabolic profile in obese postmenopausal women?
Brochu M; Tchernof A; Turner AN; Ades PA; Poehlman ET
Metabolism; 2003 May; 52(5):599-604. PubMed ID: 12759890
[TBL] [Abstract][Full Text] [Related]
18. Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome.
Cleare AJ; O'Keane V; Miell JP
Psychoneuroendocrinology; 2004 Jul; 29(6):724-32. PubMed ID: 15110921
[TBL] [Abstract][Full Text] [Related]
19. Relationships between dehydroepiandrosterone-sulphate and anthropometric, metabolic and hormonal variables in a large cohort of obese women.
Maccario M; Mazza E; Ramunni J; Oleandri SE; Savio P; Grottoli S; Rossetto R; Procopio M; Gauna C; Ghigo E
Clin Endocrinol (Oxf); 1999 May; 50(5):595-600. PubMed ID: 10468925
[TBL] [Abstract][Full Text] [Related]
20. Long-term low-dose oral administration of dehydroepiandrosterone modulates adrenal response to adrenocorticotropic hormone in early and late postmenopausal women.
Genazzani AR; Pluchino N; Begliuomini S; Stomati M; Bernardi F; Pieri M; Casarosa E; Palumbo M; Genazzani AD; Luisi M
Gynecol Endocrinol; 2006 Nov; 22(11):627-35. PubMed ID: 17145649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
